Navigation Links
Lumenis(R) Introduces Four New Products & Delivery Devices at the 2008 American Academy of Ophthalmology Annual Meeting in Atlanta, Georgia USA
Date:11/6/2008

SANTA CLARA, Calif., Nov. 6 /PRNewswire/ -- Lumenis(R) Ltd. a global developer, manufacturer and marketer of laser, light-based and radiofrequency devices for ophthalmic, surgical and aesthetic applications, announced today that it will introduce four new ophthalmic lasers and delivery devices on November 8th at the American Academy of Ophthalmology (AAO) Annual Meeting in Atlanta, Georgia.

Dov Ofer, Lumenis' President and Chief Executive Officer stated: "Lumenis is proud to be yet again at the forefront of ophthalmic laser technology with the introduction of the Selecta(R) family of ophthalmic lasers, the Novus(R) Spectra(TM) Dual-Port Photocoagulator and the LumeProbe(TM) comprehensive family of premium endo photocoagulation laser probes. This industry-leading achievement stems from Lumenis' 40-year history of ophthalmic laser innovation. In 1970, we were the first company to introduce a laser in this field; since then, we have followed with a series of additional sight-preserving milestones, including the first laser photocoagulator, laser indirect ophthalmoscope, multicolor photocoagulator, photodynamic therapy laser, the revolutionary Selective Laser Trabeculoplasty (SLT) system and solid state multicolor laser."

"At this year's AAO Meeting, we simply continue this long-standing tradition as we proudly showcase the newest additions to our existing and already robust product portfolio of ophthalmic lasers - a new and complete set of ophthalmic laser solutions. Our Selecta family of lasers for the ophthalmic practice offers it all - from ultimate simplicity, to comprehensive choice of therapy with maximum flexibility. Our new laser delivery devices are specifically designed to provide superior performance, as well as improve physician comfort during procedures," said Dov Ofer.

"Today, Lumenis also further expands its capabilities in the Retina segment with the introduction of the LumeProbe product family," said Gideon (Gidi) Sturlesi,
'/>"/>

SOURCE Lumenis Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Lumenis(R) Introduces the Newest Innovations in Fractional CO2 Laser Skin Therapy
2. Lumenis(R) Seeks Shareholder Approval of Proposed Class Action Settlement
3. Delta Dental of Illinois Introduces Smile Smart For Your Health
4. Highmark Blue Cross Blue Shield Introduces New Health Plan Comparison Tool for Consumers
5. Highmark Blue Shield Introduces New Health Plan Comparison Tool for Consumers
6. Sentillion Introduces Affordable Next Generation Healthcare Single Sign-On Solution Called expreSSO(TM)
7. GladRags Introduces the Moon Cup - An Environmentally-Sound and Safe Alternative to Disposable Feminine Hygiene Products!
8. Triveris Introduces Personal Health Record with Built-in Health Advisor
9. Verizon Introduces Broadband Video Call Center Link for Deaf or Hard-of-Hearing Customers in Mid-Atlantic Region
10. Mecklenburg EMS Introduces Most-Advanced Situational Training in America for Emergency Medical Personnel
11. Small Bone Innovations Introduces the Artelon(R) STT Spacer to Increase Treatment Options for Thumb Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... Lake Worth, FL (PRWEB) July 23, 2014 ... will take place Aug. 10-16, Millennium Treatment Group is ... Substance abuse has existed in society ever since man ... make wine. Substance abuse treatment has existed since shortly ... of recognizing a problem and then developing a way ...
(Date:7/23/2014)... July 23, 2014 A new study ... power morcellator ( http://www.injurybeacon.com/power-morcellator/ ) during minimally invasive ... throughout a woman’s body, Bernstein Liebhard LLP reports. The ... Journal of the American Medical Association, looked at 36,000 ... at 500 U.S. hospitals from 2006 to 2012. Ninety-nine ...
(Date:7/23/2014)... Alan Mozes HealthDay Reporter ... servicemen are more likely to have been exposed to some ... new survey suggests. The finding seems to apply solely ... that the finding could be a cause for concern, given ... and/or sexual abuse among the civilian population has been linked ...
(Date:7/23/2014)... YORK, NY, July 24, 2014) If past experience ... York State are about to get a lot more ... laws already on the books allowing NPs to provide ... to patient care and better relationships with physicians and ... a study from Columbia University School of Nursing, published ...
(Date:7/23/2014)... Randy Dotinga HealthDay Reporter ... A powerful drug combo may not be as effective ... on human cells suggests that one of the medications ... this study,s findings aren,t definitive, and there,s still hope ... and lumacaftor, according to the study,s senior author. ...
Breaking Medicine News(10 mins):Health News:Millennium Treatment Group Offers Tips on Choosing a Reputable Treatment Center 2Health News:Millennium Treatment Group Offers Tips on Choosing a Reputable Treatment Center 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 4Health News:Many U.S. Male Soldiers Had Troubled Childhoods, Study Finds 2Health News:Many U.S. Male Soldiers Had Troubled Childhoods, Study Finds 3Health News:New York law offers nurses more recognition, responsibility 2Health News:Cystic Fibrosis Drug Combo May Be Less Effective Than Hoped 2Health News:Cystic Fibrosis Drug Combo May Be Less Effective Than Hoped 3
... has earmarked $74 million to combat the bird flu threat ... was to announce the funding in Busan, Korea, where he ... ,International agencies, like the World Health Organization (WHO), would ... would go on a simulation exercise run by APEC to ...
... to the World Health Organization (WHO) experts, concerted ... complete eradication of the five neglected tropical diseases ... // years. , WHO has identified five ... leishmaniasis (kala azar), soil transmitted helminths (STH) and ...
... the national nursing shortage by producing more qualified nursing ... Robert W. Woodruff Foundation has awarded // $995,000 to ... support its new doctorate of nursing practice program, the ... ,Thanking the Atlanta-based Woodruff Foundation, a private organization, for ...
... by the Italian phrase 'malaria' — or 'bad air' — ... days, scientists know malaria is spread by mosquitos. // And ... the spread of a disease that kills 1 million people ... the situation is bad. The number of deaths are rising, ...
... hospital will begin performing open-heart surgeries on patients in ... new unit equipped with the // latest equipment including ... light, automatic operation bed and latest x-ray machines for ... superintendent, IGMC., ,The new unit will be launched ...
... movie may induce enough stress to interfere with your ... you sit down to watch a violent or // ... ability. ,David Beversdorf, a neurologist at the State ... and asked them to combine movie viewing with problem-solving ...
Cached Medicine News:Health News:Concerted Effort Imperative For Elimination Of Tropical Diseases: WHO 2Health News:Woodruff Foundation Grant To Support Doctorate Of Nursing Practice Program 2Health News:Malaria Vaccine May Be 10 Years Away 2Health News:Malaria Vaccine May Be 10 Years Away 3
(Date:7/23/2014)... PLAINS, N.Y. , July 23, 2014 /PRNewswire-USNewswire/ ... approval of idelalisib to treat patients with relapsed ... small lymphocytic lymphoma (SLL) is a significant advance ... Idelalisib, which goes by the trade name ... a protein that is highly expressed in many ...
(Date:7/23/2014)... July 23, 2014  Varian Medical Systems (NYSE: ... $1.02 per diluted share in the third quarter of ... about $0.06 per diluted share due to an approximately ... Varian,s existing equity investment in Augmenix, a privately-held company ... totaled $748 million for the third quarter of fiscal ...
(Date:7/23/2014)... Conn. , July 23, 2014 UBM ... – a new online community and information resource ... better manage and treat their patients with neurological ... coupled with an aging population, necessitates greater access to ... disorders.  Key statistics on neurological conditions include: ...
Breaking Medicine Technology:The Leukemia & Lymphoma Society Applauds FDA's Approval of Idelalisib To Treat Three Types of Blood Cancers 2Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 2Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 3Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 4Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 5Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 6Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 7Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 8Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 9Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 10UBM Medica US Launches NeurologyTimes.com 2UBM Medica US Launches NeurologyTimes.com 3
... Rochester Medical Implants ( http://www.rmi.us.com ), a contract manufacturer ... it has relocated corporate offices and manufacturing operations to ... the location change, the company will change its name ... The new facility is a modern 33,000-square ...
... Calif., Oct. 17, 2011 ChemoCentryx, Inc., today ... trial for CCX168, an orally-administered small molecule for ... (AAV), a disease which can lead to renal ... receptor (C5aR), a potent pro-inflammatory mediator that is ...
Cached Medicine Technology:Rochester Medical Implants Relocates to New Facility in Noblesville, IN 2ChemoCentryx Initiates Phase II Clinical Trial for CCX168, a Novel Small Molecule C5aR Antagonist for the Treatment of Vasculitis 2ChemoCentryx Initiates Phase II Clinical Trial for CCX168, a Novel Small Molecule C5aR Antagonist for the Treatment of Vasculitis 3ChemoCentryx Initiates Phase II Clinical Trial for CCX168, a Novel Small Molecule C5aR Antagonist for the Treatment of Vasculitis 4
... CO2 laser system used in neurophysiology for studying ... the amplitude and/or the duration of the stimulus ... the laser emission in an ongoing manner by ... this laser include the high repeatability of the ...
... advanced system for laser therapy available today. The ... fiber handpiece that allows to perform linear scanning ... 20% of the energy reflected by the skin. ... special gel which optimizes the optical coupling between ...
Smart Chill is a compact cooling system that provides intense localised skin cooling through a comfortable contact handpiece....
... Smart 1064 DW with the capability of ... nm) offering increased coagulative and ablative capacities.Smart 1064 ... between two different wavelengths: ordinary 1064 nm (with ... 1320 nm (with powers among 2 and 25 ...
Medicine Products: